Claims for Patent: 8,044,174

Summary for Patent: 8,044,174

Title:	Thrombopoietic compounds
Abstract:	The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
Inventor(s):	Liu; Chuan-Fa (Longmont, CO), Feige; Ulrich (Newbury Park, CA), Cheetham; Janet C. (Montecito, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	10/933,133
Patent Claims:	1. A compound that binds to an mpl receptor comprising the structure TMP.sub.1-(L.sub.1).sub.n-TMP.sub.2 wherein the C-terminus of the TMP.sub.1 peptide is linked to the N-terminus of the TMP.sub.2 peptide, optionally via L.sub.1, wherein TMP.sub.1 and TMP.sub.2 are each independently selected from the group of core compounds comprising the structure selected from the group consisting of: a) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Lys, and Val; X.sub.3 is selected from the group consisting of Gly and Ala; X.sub.4 is Pro; X.sub.5 is selected from the group consisting of Thr and Ser; X.sub.6 is selected from the group consisting of Leu, Ile, Val, Ala, and Phe; X.sub.7 is selected from the group consisting of Arg and Lys; X.sub.8 is selected from the group consisting of Gln, Asn, and Glu; X.sub.9 is selected from the group consisting of Trp, Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Ile, Val, Ala, Phe, Met, and Lys; b) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Asp, Lys, and Val; X.sub.3 is Ala; X.sub.4 is Pro; X.sub.5 is selected from the group consisting of Thr and Ser; X.sub.6 is selected from the group consisting of Leu, Ile, Val, Ala, and Phe; X.sub.7 is selected from the group consisting of Arg and Lys; X.sub.8 is selected from the group consisting of Gln, Asn, and Glu; X.sub.9 is selected from the group consisting of Trp, Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Ile, Val, Ala, Phe, Met, and Lys; C) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Asp, Lys, and Val; X.sub.3 is selected from the group consisting of Gly and Ala; X.sub.4 is Pro; X.sub.5 is Ser; X.sub.6 is selected from the group consisting of Leu, Ile, Val, Ala, and Phe; X.sub.7 is selected from the group consisting of Arg and Lys; X.sub.8 is selected from the group consisting of Gln, Asn, and Glu; X.sub.9 is selected from the group consisting of Trp, Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Ile, Val, Ala, Phe, Met, and Lys; d) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Asp, Lys, and Val; X.sub.3 is selected from the group consisting of Gly and Ala; X.sub.4 is Pro; X.sub.5 is selected from the group consisting of Thr and Ser; X.sub.6 is selected from the group consisting of Ile, Val, Ala, and Phe; X.sub.7 is selected from the group consisting of Arg and Lys; X.sub.8 is selected from the group consisting of Gln, Asn, and Glu; X.sub.9 is selected from the group consisting of Trp, Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Ile, Val, Ala, Phe, Met, and Lys; e) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Asp, Lys, and Val; X.sub.3 is selected from the group consisting of Gly and Ala; X.sub.4 is Pro; X.sub.5 is selected from the group consisting of Thr and Ser; X.sub.6 is selected from the group consisting of Leu, Ile, Val, Ala, and Phe; X.sub.7 is Lys; X.sub.8 is selected from the group consisting of Gln, Asn, and Glu; X.sub.9 is selected from the group consisting of Trp, Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Ile, Val, Ala, Phe, Met, and Lys; f) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Asp, Lys, and Val; X.sub.3 is selected from the group consisting of Gly and Ala; X.sub.4 is Pro; X.sub.5 is selected from the group consisting of Thr and Ser; X.sub.6 is selected from the group consisting of Leu, Ile, Val, Ala, and Phe; X.sub.7 is selected from the group consisting of Arg and Lys; X.sub.8 is selected from the group consisting of Gln and Asn; X.sub.9 is selected from the group consisting of Trp, Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Ile, Val, Ala, Phe, Met, and Lys; g) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Asp, Lys, and Val; X.sub.3 is selected from the group consisting of Gly and Ala; X.sub.4 is Pro; X.sub.5 is selected from the group consisting of Thr and Ser; X.sub.6 is selected from the group consisting of Leu, Ile, Val, Ala, and Phe; X.sub.7 is selected from the group consisting of Arg and Lys; X.sub.8 is selected from the group consisting of Gln, Asn, and Glu; X.sub.9 is selected from the group consisting of Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Ile, Val, Ala, Phe, Met, and Lys; and h) X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10, wherein, X.sub.2 is selected from the group consisting of Glu, Asp, Lys, and Val; X.sub.3 is selected from the group consisting of Gly and Ala; X.sub.4 is Pro; X.sub.5 is selected from the group consisting of Thr and Ser; X.sub.6 is selected from the group consisting of Leu, Ile, Val, Ala, and Phe; X.sub.7 is selected from the group consisting of Arg and Lys; X.sub.8 is selected from the group consisting of Gln, Asn, and Glu; X.sub.9 is selected from the group consisting of Trp, Tyr, Cys, Ala, and Phe; X.sub.10 is selected from the group consisting of Leu, Val, Ala, Phe, Met, and Lys; and wherein L.sub.1 is a linker; and n is 0 or 1, wherein when n is 1, L.sub.1 is independently selected from the linker groups consisting of Y.sub.n, wherein Y is a naturally occurring amino acid or a stereoisomer thereof and n is 1 through 20; and physiologically acceptable salts thereof. 2. The compound according to claim 1 wherein said TMP.sub.1 and TMP.sub.2 are independently selected from the group consisting of: X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-- X.sub.11; X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-- X.sub.10-X.sub.11-X.sub.12; X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-- X.sub.11-X.sub.12-X.sub.13; X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-- X.sub.11-X.sub.12-X.sub.13-X.sub.14-; X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X- .sub.10; X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X- .sub.9-X.sub.10-X.sub.11; X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X- .sub.10-X.sub.11-X.sub.12; X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X- .sub.10-X.sub.11-X.sub.12-X.sub.13; and X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9- X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14, wherein X.sub.2-X.sub.10 are as defined and X.sub.1 and X.sub.11-X.sub.14 are selected from the group consisting of: a) X.sub.1 is selected from the group consisting of Ile, Val, Leu, Ser, and Arg; X.sub.11 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Ser, Thr, Lys, His, and Glu; X.sub.12 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Gly, Ser, and Gln; X.sub.13 is selected from the group consisting of Arg, Lys, Thr, Val, Asn, Gln, and Gly; and X.sub.14 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Thr, Arg, Glu, and Gly; b) X.sub.1 is selected from the group consisting of Ile, Ala, Val, Leu, Ser, and Arg; X.sub.11 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Thr, Lys, His, and Glu; X.sub.12 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Gly, Ser, and Gln; X.sub.13 is selected from the group consisting of Arg, Lys, Thr, Val, Asn, Gln, and Gly; and X.sub.14 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Thr, Arg, Glu, and Gly; and c) X.sub.1 is selected from the group consisting of Ile, Ala, Val, Leu, Ser, and Arg; X.sub.11 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Ser, Thr, Lys, His, and Glu; X.sub.12 is selected from the group consisting of Ala, Ile, Val, Leu, Gly, Ser, and Gln; X.sub.13 is selected from the group consisting of Arg, Lys, Thr, Val, Asn, Gln, and Gly; and X.sub.14 is selected from the group consisting of Ala, Ile, Val, Leu, Phe, Thr, Arg, Glu, and Gly. 3. The compound according to claim 1 wherein said TMP.sub.1 and/or TMP.sub.2 are derivatized as set forth in one or more of the following: one or more of the peptidyl [--C(O)NR--] linkages (bonds) have been replaced by a non-peptidyl linkage selected from the group consisting of: a --CH.sub.2-carbamate linkage [--CH.sub.2--OC(O)NR--]; a phosphonate linkage; a --CH.sub.2-sulfonamide [--CH.sub.2--S(O).sub.2NR--] linkage; a urea [--NHC(O)NH--] linkage; a --CH.sub.2-secondary amine linkage; and an alkylated peptidyl linkage [--C(O)NR.sup.6-- where R.sup.6 is lower alkyl]; the N-terminus is a --NRR.sup.1 group; to a --NRC(O)R group; to a --NRC(O)OR group; to a --NRS(O).sub.2R group; to a --NHC(O)NHR group where R and R.sup.1 are hydrogen and lower alkyl with the proviso that R and R.sup.1 are not both hydrogen; to a succinimide group; to a benzyloxycarbonyl-NH-- (CBZ--NH--) group; or to a benzyloxycarbonyl-NH-- group having from 1 to 3 substituents on the phenyl ring selected from the group consisting of lower alkyl, lower alkoxy, chloro, and bromo; the C terminus is --C(O)R.sup.2 where R.sup.2 is selected from the group consisting of lower alkoxy and --NR.sup.3R.sup.4 where R.sup.3 and R.sup.4 are independently selected from the group consisting of hydrogen and lower alkyl. 4. The compound according to claim 1 wherein all of the amino acids have a D configuration. 5. The compound according to claim 1 wherein at least one of the amino acids has a D configuration. 6. The compound according to claim 1 wherein L.sub.1 comprises ((Gly).sub.n, wherein n is 1 through 20, and when n is greater than 1, up to half of the Gly residues may be substituted by another amino acid selected from the remaining 19 natural amino acids or a stereoisomer thereof. 7. The compound according to claim 1 wherein L.sub.1 is selected from the group consisting of TABLE-US-00012 (Gly).sub.3Lys(Gly).sub.4; (SEQ ID NO: 6) (Gly).sub.3AsnGlySer(Gly).sub.2; (SEQ ID NO: 7) (Gly).sub.3Cys(Gly).sub.4; (SEQ ID NO: 8) and GlyProAsnGly. (SEQ ID NO: 9) 8. The compound according to claim 1 wherein L.sub.1 comprises a Cys residue.

Details for Patent 8,044,174

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NPLATE	romiplostim	For Injection	125268	08/22/2008		2018-10-23
Amgen, Inc.	NPLATE	romiplostim	For Injection	125268	10/17/2019		2018-10-23

International Patent Family for US Patent 8,044,174

Country	Patent Number	Estimated Expiration
Argentina	020934
Austria	348163
Australia	1223900